Wednesday, February 23, 2011

Hologic Medical Device Company Intelligence Report


Hologic Medical Device Company Intelligence Report

Hologic develops and manufactures medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. Through several key acquisitions, the company has increased its revenues from US$288 million in 2005 to more than US$1,670 million in 2008.
Hologic has four reporting segments: Breast Health (formerly Mammography/Breast Care), Diagnostics, GYN Surgical and Skeletal Health. The Diagnostics and GYN Surgical reporting segments were previously part of Cytyc. The AEG and MammoSite operations (the latter, formerly a part of Cytyc) are now included in Breast Health, and the osteoporosis assessment, mini C-arm and magnetic resonance imaging (MRI) product lines are included in Skeletal Health.
Hologic’s Breast Health business produces a portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), breast biopsy guidance systems, minimally-invasive breast biopsy and tissue extraction devices and breast brachytherapy products.
The Diagnostics product segment includes the ThinPrep System, which is primarily used in cytology applications, such as cervical cancer screening, and the FullTerm Fetal Fibronectin Test, which offers clinical benefits for the assessment of the risk of pre-term birth. Through the acquisition of Third Wave, Hologic added in vitro diagnostic devices using Third Wave’s Invader technology, allowing researchers to create assays to perform hepatitis C virus genotyping, inherited disorders testing and testing for other mutations associated with genetic predispositions and other diseases such as cystic fibrosis.
The GYN Surgical business includes the NovaSure Impedance Controlled RF Ablation System, which enables physicians to treat women suffering from excessive menstrual bleeding, and the Adiana Complete Transcervical Sterilization (TCS) System, which is a form of permanent female contraception intended as an alternative to tubal ligation for which Hologic is seeking PMA from the FDA.
The Skeletal Health division includes dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, Fluoroscan mini C-arm imaging products and the Esaote line of extremity MRI systems that are manufactured by an original equipment manufacturer (OEM).
Headquartered in Bedford, Massachusetts, Hologic employs more than 4,000 employees worldwide. The company’s common stock is listed on the Nasdaq Global Select Market.
Buy Now: Market Research

Related Reports